MedImmune named Scott Carmer EVP commercial operations, with responsibility for all sales, marketing, sales operations and global marketing functions along with commercialization of pipeline products.
Carmer brings a wealth of marketing experience with big biotechs. He joins the AstraZeneca-owned biologics firm from Genentech, where he was VP sales and marketing for the rheumatology franchise. He’s also held senior roles in global marketing and brand management at Amgen and in sales, marketing, global business development, commercial operations and managed care at GSK.
Carmer replaces Peter Greenleaf, who was elevated to president of MedImmune in February. In a statement, Greenleaf praised “the breadth of Scott’s biologics and global commercial experience.”
Among his first tasks could be commercialization of motavizumab, the monoclonal antibody the company hopes will be a Synagis successor, pending approval. A decision is expected towards the end of the month, though an FDA panel pooh-poohed the product, for the treatment of a dangerous respiratory ailment in infants, back in June.
